Capital Fund Management (CFM)
CTMX icon

Capital Fund Management (CFM)’s CytomX Therapeutics CTMX Stock Holding History

Capital Fund Management (CFM)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,443
Closed -$153K – 1624
2019
Q4 		$153K Sell
18,443
-3,857
-17% -$26K ﹤0.01% 1763
2019
Q3 		$165K Buy
+22,300
New +$220K ﹤0.01% 1591
2018
Q3 		– Sell
-10,800
Closed -$247K – 2014
2018
Q2 		$247K Buy
+10,800
New +$276K ﹤0.01% 1853

Other funds holding CTMX

Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Fund Management (CFM)'s CTMX Position: Q1 2020 in Review

Capital Fund Management (CFM) sold out of CytomX Therapeutics (CTMX) in Q1 2020, closing a stake of 18,443 shares — an estimated $153K sold.

Capital Fund Management (CFM) first reported a position in CTMX in Q2 2018 and held it in 3 quarters. The position peaked at $247K in Q2 2018. 117 funds tracked by Wall St. Rank hold CTMX as of Q1 2020.

  • Capital Fund Management (CFM) reported no remaining CytomX Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 18,443 CytomX Therapeutics shares in Q1 2020, an estimated $153K.
  • Capital Fund Management (CFM) first reported a position in CytomX Therapeutics in Q2 2018 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s CytomX Therapeutics position peaked at $247K in Q2 2018.
  • 117 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2020, filed 13 May 2020.